Work

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel

Year: 2014

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-014-2572-z

Authors: John Sarantopoulos, Alain C. Mita, James L. Wade, John C. Morris, Olivier Rixe, Monica M. Mita, Jean-François Dedieu, Claudine Wack, Laurent Kassalow, A. Craig Lockhart

Institutions: The University of Texas at San Antonio Health Science Center, Cedars-Sinai Medical Center, University of Cincinnati, Augusta University, Sanofi (France), Sanofi (United States), Washington University in St. Louis, Alvin J. Siteman Cancer Center

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Sanofi, University of Texas Health Science Center at San Antonio, National Cancer Institute

Award: Mays Cancer Center at UT Health SA

OpenAlex ID: W2044418376

FWCI: 3.435

Cites: 20

Cited by: 14

Related to: 10